11.47
전일 마감가:
$11.14
열려 있는:
$11.25
하루 거래량:
21,360
Relative Volume:
0.41
시가총액:
$38.86M
수익:
-
순이익/손실:
$-58.52M
주가수익비율:
-5.488
EPS:
-2.09
순현금흐름:
$-45.03M
1주 성능:
+1.50%
1개월 성능:
+16.09%
6개월 성능:
+1,584%
1년 성능:
+962.04%
Nextcure Inc Stock (NXTC) Company Profile
명칭
Nextcure Inc
전화
240-399-4900
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
NXTC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
NXTC
Nextcure Inc
|
11.47 | 37.75M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-03-05 | 업그레이드 | Truist | Hold → Buy |
| 2021-01-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-07-16 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-07-13 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-13 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-06-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-03-24 | 개시 | The Benchmark Company | Buy |
| 2020-03-02 | 개시 | ROTH Capital | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-05 | 개시 | Needham | Buy |
| 2019-11-26 | 개시 | BTIG Research | Buy |
| 2019-07-09 | 개시 | BofA/Merrill | Buy |
| 2019-06-03 | 개시 | Morgan Stanley | Overweight |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Nextcure Inc 주식(NXTC)의 최신 뉴스
NextCure (NASDAQ:NXTC) Upgraded to “Hold” at Wall Street Zen - Defense World
What sentiment indicators say about NextCure Inc. stockStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
How analysts rate NextCure Inc. stock todayJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - Newser
What is the fair value of NextCure Inc. stock nowJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
Will NextCure Inc. stock deliver long term returnsWeekly Profit Report & High Return Trade Guides - Newser
NextCure stock plunges to 52-week low, hits $0.69 - MSN
NextCure files for offering of up to 2.52 million shares of common stock by selling stockholdersSEC filing - marketscreener.com
[S-3] NextCure, Inc. Shelf Registration Statement | NXTC SEC FilingForm S-3 - Stock Titan
Piper Sandler Keeps Their Buy Rating on NextCure (NXTC) - theglobeandmail.com
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
NextCure (Nasdaq: NXTC) in fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
NextCure Raises $21.5M in Private Placement - MSN
Will NextCure Inc. stock maintain momentum in 2025Trade Entry Summary & Reliable Trade Execution Plans - newser.com
Can NextCure Inc. stock sustain market leadershipQuarterly Portfolio Review & Expert Curated Trade Setup Alerts - newser.com
FY2025 EPS Estimates for NextCure Boosted by HC Wainwright - Defense World
How currency fluctuations impact NextCure Inc. stockEarnings Overview Report & Precise Buy Zone Tips - newser.com
How NextCure Inc. stock reacts to inflationary pressuresJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
NextCure Inc. recovery potential after sell offMarket Weekly Review & Fast Entry High Yield Stock Tips - newser.com
Will NextCure Inc. stock gain from lower inflationProfit Target & AI Enhanced Trading Alerts - newser.com
Evaluating NextCure Inc. with trendline analysisEarnings Growth Report & Real-Time Volume Analysis - newser.com
Comparing NextCure Inc. in custom built stock radarsJuly 2025 Sector Moves & Low Volatility Stock Recommendations - newser.com
A activityJuly 2025 Market Mood & Real-Time Volume Trigger Notifications - newser.com
NextCure secures $21.5 million in private placement to extend cash runway - Investing.com Canada
NextCure, Inc. Secures $21.5 Million in Private Placement, Extending Cash Runway into First Half of 2027 - Quiver Quantitative
NextCure (Nasdaq: NXTC) PIPE Extends Runway to 1H 2027 Ahead of 2026 ADC POC Data - Stock Titan
How to integrate NextCure Inc. into portfolio analysis toolsTake Profit & Risk Adjusted Buy/Sell Alerts - newser.com
NextCure, Inc. announced that it has received $21.498209 million in funding from Ikarian Capital, LLC, Squadron Capital Management Llc, Affinity Asset Advisors, LLC, Exome Asset Management LLC - MarketScreener
How institutional ownership impacts NextCure Inc. stockBond Market & Verified Momentum Stock Watchlist - newser.com
Predicting NextCure Inc. trend using moving averagesRisk Management & Safe Entry Zone Identification - newser.com
Has NextCure Inc. found a price floorStock Surge & Long-Term Safe Investment Plans - newser.com
NextCure Advances Cancer Therapies Amid Financial Adjustments - MSN
NextCure raises $21.5 million in private placement to fund ADC programs - Investing.com Canada
How sentiment analysis helps forecast NextCure Inc.Quarterly Performance Summary & Accurate Technical Buy Alerts - newser.com
Nextcure Inc (NXTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):